Why is PRV131 Needed?



- Fast-growing tumors such as lung malignancies remain difficult to manage, even after patients receive surgery, radiation, and chemotherapy
- There is a high rate of local recurrence, with over 30% of patients dying due to local lung tumors
- Currently available therapies aren't "enough" to prevent tumors from growing back in a short period of time, and often make patients extremely sick with toxic side effects
- Need for treating patient populations that cannot tolerate systemic anticancer treatments. This includes children and the elderly.

Preclinical Proof of Concept

PRV131 was studied in several animal models to ensure its safety, efficacy, and superiority to existing chemotherapy (cisplatin). The results of one study are shown below. Aggressive colon cancer (MC38) cells were implanted into mouse flanks and once tumors grew, they were treated with a single intratumoral injection of PRV131 or solution cisplatin (standard chemotherapy). Mice were monitored for up to 60 days to assess safety (survival) and efficacy (tumor growth inhibition).



- 80% of PRV131 treated mice survived to day 60 post inoculation
- **No detectable tumor found in 60% of PRV131 treated mice ≥ 38 days post treatment**
- PRV131 400 µg has dramatically improved efficacy and survival than all control groups

Privo technologies

Tough On Cancer, Easy On Patients

PRV131 – Sustained-Release, Localized, Super-Concentrated Intratumoral Cisplatin Injectable

What is PRV131?

PRV131 intratumoral injectable treatment will transform the landscape of cancer care for solid tumors. PRV131 is a preclinical asset with proven efficacy and safety in several animal models. Key highlights include:

- **A single, local injection controls and shrinks tumors for >28 days**
- Nanotechnology allows for super-concentrated chemotherapy to be delivered and retained in the tumor, avoiding systemic exposure

PRV131 Mechanism of Action
PRV131 contains cisplatin-encapsulating nanoparticles and matrix polymers that allow for superior local drug retention in solid tumors with minimal systemic toxicity. PRV131 significantly improves survival and tumor control in murine tumor models compared to solution cisplatin.

What Sets PRV131 Apart from Other Intratumoral Therapies?
A single injection of PRV131 is able to release cisplatin for >28 days to provide a durable antitumor effect.

Complete Tumor Regression
Of animals treated with a single injection of PRV131, 60% had no clinically observable tumor. Conversely, all of the mice (100%) treated with solution cisplatin had clinically observable tumors.

Clinical Use/Initial Indication
PRV131 is reconstituted from a powder provided in a syringe using a proprietary diluent. This process is performed in the clinic and takes 30 seconds to make a homogenous suspension. The initial indication for PRV131 is treatment of lung cancer such as malignant airway obstruction (MAO).

Injectability
Privo has tested PRV131 injection via bronchoscopes and syringes with no failures in injectability through needles 18 G to 27 G.

Validated Platform Technology – Tumor Reduction
PRV131 is a derivative of Privo's platform technology. Another product derived from this technology (PRV111) has been studied and its efficacy and safety was tested in human trial, successfully meeting all the endpoints (NCT03502148). Published results can be found in Nature Communications. Oral cancer tumors were treated with topical PRV111 prior to surgery, and tumors shrunk on average 69% in 7 days (Below).



Validated Platform Technology – Immunomodulation
High levels of tumor-infiltrating lymphocytes (TILs) generally correspond with improved clinical outcome and overall survival in patients with head and neck cancer. PRV111 therapy caused a substantial increase in TILs post-treatment (Below).



Next Steps?
Privo is fundraising to initiate an in-human clinical trial with PRV131 in 2024